Lpath Granted Key European Patent Related to iSONEP Drug

Lpath Granted Key European Patent Related to iSONEP Drug Program 
New Patent Provides Coverage for Lpath's Anti-S1P Antibody,
Sonepcizumab, in the Treatment of a Wide Variety of Ocular Disorders 
SAN DIEGO, CA -- (Marketwire) -- 12/05/12 --  Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
received official notification from European Patent Office (EPO) that
the company has been issued a key patent covering monoclonal
antibodies against sphingosine-1-phosphate (S1P), including
sonepcizumab(TM). S1P is a bioactive lipid that has been validated as
a target in multiple disease states. 
This newly granted patent, European patent No. 1 948 234, claims,
among other things, humanized monoclonal antibodies directed against
S1P for use in treating a wide range of ocular conditions, including
age-related macular degeneration (AMD), diabetic retinopathy and
others. 
"This key patent provides exclusivity in Europe for our lead S1P
program in wet AMD in which dysfunctional angiogenesis, inflammation
and scarring contribute to disease progression," said Roger
Sabbadini, Lpath's vice president, founder, and inventor of the
granted patent. "It also provides us exclusivity in our pursuit of
other ocular disorders where we believe dysfunctional levels of S1P
may be involved in pathogenesis of disease."  
ASONEP(TM) and iSONEP(TM) are different formulations of sonepcizumab,
a first-in-class therapeutic antibody against S1P developed by
Lpath's ImmuneY2(TM) drug-discovery engine. Antibodies developed via
this discovery engine are designed to target bioactive signaling
lipids, such as S1P, that are involved in the proliferation and
spread of cancer, AMD, inflammatory and auto-immune disorders, and
many other diseases. 
Lpath recently completed two early-stage clinical trials using the
two anti-S1P antibody formulations: iSONEP was evaluated in a Phase 1
trial in wet-AMD subjects, and ASONEP was evaluated in a Phase 1
trial in cancer subjects. 
Lpath has initiated a Phase 2 clinical trial for iSONEP, called
Nexus, which is evaluating the anti-S1P antibody's safety and
efficacy in wet-AMD patients. Lpath entered into an agreement with
Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option
for a worldwide license to develop and commercialize iSONEP.  
Lpath is also independently pursuing an ASONEP Phase 2 trial in renal
cell carcinoma and will open this trial soon.  
Lpath was also recently granted a Russian patent (2009120052) and a
U.S. patent (8,222,373) with composition and methods claims relating
to sonepcizumab. 
About Lpath's Patent Portfolio
 Over the course of the company's
development, Lpath has achieved a broad and deep intellectual
property position in the bioactive-lipid area. The company's
comprehensive patent portfolio now includes 33 issued patents
(including nine international) and 109 patent applications (including
82 international). These patents primarily relate to the use of
reagents and methods designed to interfere with the actions of
bioactive lipids involved in human disease. Lpath's intellectual
property portfolio includes coverage of compositions of matter that
specifically bind to sphingolipids and sphingolipid metabolites.
These compositions, including antibodies, could be used in the
diagnosis and treatment of various diseases and disorders, including
cardiovascular and cerebrovascular disease, cancer, inflammation,
autoimmune disorders, ocular disease, and angiogenesis.  
Lpath has also obtained issued patent claims on sphingolipid targets
(e.g., receptors and signaling sphingolipids) and methods for using
such targets in drug-discovery screening efforts.  
The company believes that its patent portfolio provides broad and
commercially significant coverage of antibodies, receptors, enzymes,
and other moieties that bind to a lysolipid (or a sphingolipid
metabolite) for diagnostic, therapeutic, or screening purposes. 
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics, an
emerging field of medicine that targets bioactive signaling lipids
for treating a wide range of human disease. Lpath's ImmuneY2(TM)
drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute
to disease. The company has developed three drug candidates:
iSONEP(TM) is currently in a Phase 2 trial for wet AMD; ASONEP(TM)
will soon begin a Phase 2 trial in Renal Cell Carcinoma patients; and
Lpathomab is a preclinical drug candidate that holds promise in
neuropathic pain, neurotrauma, and other diseases. For more
information, visit www.Lpath.com. 
About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description
of historical facts are forward-looking statements. These include
statements regarding: the protection against competition afforded by
issued patents; the eventual commercial viability of the Company's
drug programs; and the Company's ability to complete additional
discovery and development activities for drug candidates utilizing
its proprietary ImmuneY2 drug discovery process. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in the Company's business,
including, without limitation: the outcome of the final analyses of
the data from the Phase 1 clinical trial may vary from the Company's
initial conclusions; the results of any future clinical trials for
iSONEP or ASONEP may not be favorable and the Company may never
receive regulatory approval for iSONEP or ASONEP or any of its drug
candidates; and the Company's may not be able to secure the funds
necessary to support its clinical trial and product development
plans. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q filed with the SEC. Such documents may
be read free of charge on the SEC's web site at www.sec.gov. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200
spancoast@Lpath.com 
Lpath Investor Relations
Liolios Group, Inc. 
(949) 574-3860
lptn@liolios.com 
Ron Both: ron@liolios.com 
Geoffrey Plank: geoffrey@liolios.com
 
 
Press spacebar to pause and continue. Press esc to stop.